Metformin May Mimic Exercise Benefits by Boosting Lac-Phe Levels, Study Suggests

What if a drug could replicate the benefits of exercise without the physical effort? A groundbreaking study suggests that metformin, a widely prescribed medication for type 2 diabetes, may do precisely that. Researchers at the University of Miami Miller School of Medicine have uncovered evidence that the drug—priced as low as 2p per pill—can elevate levels of a molecule called Lac-Phe, which is typically released during intense physical activity. This discovery raises intriguing questions about how a simple, affordable treatment might help millions of people who are unable to exercise due to illness, disability, or other constraints.

The study, published in the journal *EMBO Molecular Medicine*, analyzed blood samples from 29 men diagnosed with prostate cancer. While metformin did not directly treat the cancer, it significantly increased Lac-Phe levels in these patients. Known to spike after rigorous exercise, Lac-Phe has been linked to improved metabolic function, appetite suppression, and weight loss. Dr. Marijo Bilusic, a medical oncologist and lead author of the study, emphasized the clinical significance of these findings. "Seeing a metabolic signal that mirrors what we associate with intense exercise was striking," she said. For patients whose treatments or symptoms limit physical activity, this effect could be especially meaningful.

The implications extend beyond prostate cancer. Metformin is already used by nearly three million people in the UK alone to manage type 2 diabetes. Its ability to lower insulin levels—thereby reducing the proliferation of malignant cells—has sparked interest in its potential as a cancer-fighting drug. Earlier studies have linked it to a reduced risk of esophageal and prostate cancers, suggesting a broader role in oncology. However, this new research focuses on its metabolic benefits, which could be equally transformative for patients undergoing treatment.

David Lombard, a Sylvester researcher and professor of pathology at the Miller School, highlighted the importance of understanding metabolism's role in disease. "Metabolism is involved in everything cells do," he said. The study's findings suggest that Lac-Phe may serve as a biomarker for how metformin influences metabolic pathways in cancer patients. This insight could lead to tailored therapies that support both tumor suppression and overall metabolic health.

For those who cannot engage in physical activity, the drug's ability to mimic exercise could be life-changing. Priyamvada Rai, a professor of radiation oncology at the Miller School, noted that supporting metabolic health during treatment may improve patients' quality of life. "Even if it doesn't directly change tumor growth, it can influence how patients tolerate treatment and how they feel over time," she explained. This aligns with a growing recognition that cancer care must address not only tumors but also the body's broader physiological needs.

Metformin's potential applications are not limited to oncology. It is also used by the NHS to improve fertility in women with polycystic ovary syndrome (PCOS), a condition that disrupts hormonal balance and can lead to infertility. The drug's ability to regulate insulin and reduce inflammation may explain its dual role in metabolic and reproductive health. Yet, despite its widespread use, questions remain about its full range of benefits and risks.

As researchers continue to explore metformin's effects, the drug's affordability and accessibility make it a compelling candidate for further investigation. Could it one day be prescribed not only for diabetes but also as a preventive measure against metabolic disorders or even cancer? The answers may lie in understanding how Lac-Phe and other molecules interact with the body's systems. For now, the study offers a tantalizing glimpse into a future where medication might help bridge the gap between physical inactivity and health.

The research team has called for more studies to confirm these findings and explore their long-term implications. While metformin is not a substitute for exercise, it may offer a lifeline to those who cannot engage in physical activity. As scientists delve deeper into its mechanisms, one thing is clear: the boundaries between medicine and movement are blurring, opening new possibilities for treating some of the most complex challenges in modern healthcare.